ENG
Oxytocin Market: Global Industry Analysis and Forecast (2024-2030) by Indication, Distribution Channel, and Region.
Oxytocin Market size was valued at US$ 29.50 Billion in 2023 and the Oxytocin revenue is expected to grow at 5.4% through 2024 to 2030, reaching nearly US$ 42.63 Billion.
Format : PDF | Report ID : SMR_321
Oxytocin Market Definition & Overview:
The neuropeptide hormone oxytocin has sparked a spike in market interest due to its pivotal role in human evolution. The peptide hormone has a role in a variety of physiological functions. It helps in birth, lactation, and maternal behaviour, among other things. For example, the oxytocin market has grown as a result of research into broadening oxytocin's roles beyond initiating birth.
The race for the global oxytocin market gathered up speed significantly. This is primarily owing to scientists looking into the significance of oxytocin in human well-being, considering how important it may be in influencing social behaviours and modifying emotions in humans and other species. Exogenously delivered oxytocin has been shown to improve a variety of social behaviours. The healthcare sector, in particular, is banking on oxytocin's enormous potential in mental illnesses, as a cancer biomarker, and in the development of a wide variety of treatments, including analgesics.
To get more Insights: Request Free Sample Report
Oxytocin Market Dynamics:
The need for synthetic oxytocin has risen in response to an increase in C-sections, which has been aided by FDA-approved formulations. Human illness research has been a leading indicator of the oxytocin market's growing revenue potential. In recent years, a slew of neuroscientific studies has looked into new avenues in novel treatment techniques for mental diseases, with oxytocin assisting in the discovery of new therapeutic targets. As a result, the oxytocin market has opened up new income opportunities in autism, depression, schizophrenia, borderline personality disorder, and social anxiety disorders.
One of the main factors driving the oxytocin market is a growing interest in social cognition. A rising number of placebo trials is accelerating market progress. Advances in neuroimaging technology have fuelled a lot of progress in this field. A variety of animal research has broadened the oxytocin market's possibilities. In addition, the rising number of induced births in developing countries has boosted the demand for hospitals and institutional delivery in many regions of the world. In the forecast period, advances in the neurobiology of oxytocin effects will increase revenue potential in the oxytocin market.
Oxytocin Market Segment Analysis:
By Indication, PPH (postpartum haemorrhage) is expected to be favourable in the oxytocin market during the forecast period. Postpartum haemorrhage affects around 3-5 percent of obstetric patients, accounting for a quarter of all maternal fatalities worldwide. As a result, efforts are being made to avoid such deaths, offering a substantial boost to postpartum haemorrhage management. Antepartum haemorrhage (APH) is also gaining pace, with an incremental potential worth US$ 13.4 million expected by 2030. Antepartum haemorrhage puts both the mother and the foetus in danger, therefore it's critical to treat it, pushing drug companies to come up with new formulations.
By Distribution Channel, The major point of contact for obtaining prescription oxytocin-controlling medications is hospital pharmacies. Hospital pharmacies sell more than three out of every five pharmaceuticals, owing to a higher likelihood of availability than alternative distribution channels. However, as a result of the rapid growth of virtual market spaces in reaction to the coronavirus epidemic, online pharmacies are gaining traction. To meet the rising demand for oxytocin formulations, platforms like CVS Pharmacies and Walgreens have improved their web presence.
Oxytocin Market Regional Insights:
In 2023, the North American oxytocin market reached $5 billion in sales, owing to increased rates of delivery and pregnancy-related problems. Pregnant women with pre-existing diseases are becoming more common, according to Blue Cross Blue Shield. In addition, the number of women who had both delivery and pregnancy problems increased by more than 31% from 2014 to 2018. Pre-eclampsia (19%) and gestational diabetes (16.6%) are also included as the leading causes of pregnancy complications, according to the survey. Pharmaceutical producers in the United States are responding to these developments by increasing synthetic oxytocin manufacturing.
By 2027, the European oxytocin market is expected to grow at a rate of nearly 8% in terms of value. Promising developments in maternity care have aided in the growth of oxytocin product sales across the continent. The maternal mortality rate fell roughly in half between 2000 and 2015, from 33 to 16 deaths per 100,000 live births. Women of 'non-western' ancestry, on the other hand, have a 60 percent greater death rate than their European counterparts.
The objective of the report is to present a comprehensive analysis of the Oxytocin Market to the stakeholders in the industry. The report provides trends that are most dominant in the Oxytocin Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Oxytocin Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Oxytocin Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Oxytocin Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Oxytocin Market Scope:
|
Oxytocin Market |
|
|
Market Size in 2023 |
USD 29.50 Bn. |
|
Market Size in 2030 |
USD 42.63 Bn. |
|
CAGR (2024-2030) |
5.4% |
|
Historic Data |
2018-2022 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2030 |
|
Segment Scope |
by Indication
|
|
By Distribution Channel
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Oxytocin Market Players:
- Pfizer Inc. (United States)
- Novartis AG (Switzerland)
- Fresenius Kabi LLC (United States)
- Hikma Pharmaceuticals PLC (United Kingdom)
- Endo International Plc. (Par Sterile Products, LLC) (Ireland)
- Teva Pharmaceuticals Ltd. (Jerusalem)
- Mylan N.V. (United States)
- Wockhardt Ltd. (Mumbai)
- Sun Pharmaceutical Industries Ltd. (Mumbai)
- Yuhan Corporation (South Korea)
Frequently Asked Questions
One of the main factors driving the oxytocin market is a growing interest in social cognition.
In 2023, the North American oxytocin market reached $5 billion in sales, owing to increased rates of delivery and pregnancy-related problems.
Promising developments in maternity care have aided in the growth of oxytocin product sales across the continent.
Pfizer Inc., Novartis AG, Ferring B.V., Fresenius Kabi LLC, harmaceuticals Ltd., Mylan N.V., Wockhardt Ltd., Sun PhHikma Pharmaceuticals PLC, Endo International Plc. (Par Sterile Products, LLC), Teva Parmaceutical Industries Ltd. and Yuhan Corporation
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1.Research Process
2.2.Global Oxytocin Market: Target Audience
2.3.Global Oxytocin Market: Primary Research (As per Client Requirement)
2.4.Global Oxytocin Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1. Market Share Analysis, By Value,2023-2030
4.1.1.Market Share Analysis, By Region, By Value,2023-2030 (In %)
4.1.1.1.North America Market Share Analysis, By Value,2023-2030 (In %)
4.1.1.2.Europe Market Share Analysis, By Value,2023-2030 (In %)
4.1.1.3.Asia Pacific Market Share Analysis, By Value,2023-2030 (In %)
4.1.1.4.South America Market Share Analysis, By Value,2023-2030 (In %)
4.1.1.5.Middle East and Africa Market Share Analysis, By Value,2023-2030 (In %)
4.1.2.Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.1. North America Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.1.1.USA Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.1.2.Canada Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.1.3.Mexico Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2. Europe Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.1.UK Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.2.France Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.3.Germany Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.4.Italy Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.5.Spain Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.6.Sweden Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.7.Austria Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.2.8.Rest of Europe Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3. Asia Pacific Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.1.China Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.2.India Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.3.Japan Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.4.South Korea Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.5.Australia Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.6.ASEAN Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.3.7.Rest of APAC Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.4. South America Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.4.1.Brazil Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.4.2.Argentina Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.4.3.Rest of South America Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.5. Middle East and Africa Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.5.1.South Africa Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.5.2.GCC Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.5.3.Egypt Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.5.4.Nigeria Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.2.5.5.Rest of Middle East and Africa Market Share Analysis, By Indication, By Value,2023-2030 (In %)
4.1.3.Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.North America Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.1.1.USA Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.1.2.Canada Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.1.3.Mexico Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2. Europe Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.1.UK Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.2.France Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.3.Germany Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.4.Italy Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.5.Spain Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.6.Sweden Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.7.Austria Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.2.8.Rest of Europe Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3. Asia Pacific Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.1.China Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.2.India Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.3.Japan Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.4.South Korea Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.5.Australia Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.6.ASEAN Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.3.7.Rest of APAC Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.4. South America Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.4.1.Brazil Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.4.2.Argentina Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.4.3.Rest of South America Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.5. Middle East and Africa Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.5.1.South Africa Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.5.2.GCC Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.5.3.Egypt Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.5.4.Nigeria Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.1.4.5.5.Rest of Middle East and Africa Market Share Analysis, By Distribution Channel, By Value,2023-2030 (In %)
4.2. Stellar Competition matrix
4.2.1.Global Stellar Competition Matrix
4.2.2.North America Stellar Competition Matrix
4.2.3.Europe Stellar Competition Matrix
4.2.4.Asia Pacific Stellar Competition Matrix
4.2.5.South America Stellar Competition Matrix
4.2.6.Middle East and Africa Stellar Competition Matrix
4.3. Key Players Benchmarking
4.3.1.Key Players Benchmarking By Indication, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
4.4. Mergers and Acquisitions in Industry
4.4.1.M&A by Region, Value and Strategic Intent
4.5. Market Dynamics
4.5.1.Market Drivers
4.5.2.Market Restraints
4.5.3.Market Opportunities
4.5.4.Market Challenges
4.5.5.PESTLE Analysis
4.5.6.PORTERS Five Force Analysis
4.5.7.Value Chain Analysis
Chapter 5 Global Oxytocin Market Segmentation: By Indication Type
5.1. Global Oxytocin Market, By Indication Type, Overview/Analysis,2023-2030
5.2. Global Oxytocin Market, By Indication Type, By Value, Market Share (%),2023-2030 (USD Million)
5.3. Global Oxytocin Market, By Indication Type, By Value, -
5.3.1.Indication Type Segment 1
5.3.2.Indication Type Segment 2
Chapter 6 Global Oxytocin Market Segmentation: By Distribution Channel
6.1. Global Oxytocin Market, By Distribution Channel, Overview/Analysis,2023-2030
6.2. Global Oxytocin Market Size, By Distribution Channel, By Value, Market Share (%),2023-2030 (USD Million)
6.3. Global Oxytocin Market, By Distribution Channel, By Value, -
6.3.1.Distribution Channel Segment 1
6.3.2.Distribution Channel Segment 2
Chapter 7 Global Oxytocin Market Segmentation: By Region
7.1. Global Oxytocin Market, By Region – North America
7.1.1.North America Oxytocin Market Size, By Indication Type, By Value,2023-2030 (USD Million)
7.1.2.North America Oxytocin Market Size, By Distribution Channel, By Value,2023-2030 (USD Million)
7.1.3.By Country – U.S.
7.1.3.1.U.S. Oxytocin Market Size, By Indication Type, By Value, 2023-2030 (USD Million)
7.1.3.2.U.S. Oxytocin Market Size, By Distribution Channel, By Value,2023-2030 (USD Million)
7.1.3.3.Canada Oxytocin Market Size, By Value,2023-2030 (USD Million)
7.1.3.4.Mexico Oxytocin Market Size, By Value,2023-2030 (USD Million)
7.2. Europe Oxytocin Market Size, By Value,2023-2030 (USD Million)
7.2.1.UK
7.2.2.France
7.2.3.Germany
7.2.4.Italy
7.2.5.Spain
7.2.6.Sweden
7.2.7.Austria
7.2.8.Rest of Europe
7.3. Asia Pacific Oxytocin Market Size, By Value,2023-2030 (USD Million)
7.3.1.China
7.3.2.India
7.3.3.Japan
7.3.4.South Korea
7.3.5.Australia
7.3.6.ASEAN
7.3.7.Rest of APAC
7.4. Middle East and Africa Oxytocin Market Size, By Value,2023-2030 (USD Million)
7.4.1.South Africa
7.4.2.GCC
7.4.3.Egypt
7.4.4.Nigeria
7.4.5.Rest of Middle East and Africa
7.5. South America Oxytocin Market Size, By Value,2023-2030 (USD Million)
7.5.1.Brazil
7.5.2.Argentina
7.5.3.Rest of South America
Chapter 8 Company Profiles
8.1. Key Players
8.1.1.Pfizer Inc.
8.1.1.1.Company Overview
8.1.1.2.Product Portfolio
8.1.1.3.Financial Overview
8.1.1.4.Business Strategy
8.1.1.5.Key Developments
8.1.2.Pfizer Inc.
8.1.3.Novartis AG
8.1.4.Fresenius Kabi LLC
8.1.5.Hikma Pharmaceuticals PLC
8.1.6.Endo International Plc. (Par Sterile Products, LLC)
8.1.7.Teva Pharmaceuticals Ltd.
8.1.8.Mylan N.V.
8.1.9.Wockhardt Ltd.
8.1.10.Sun Pharmaceutical Industries Ltd.
8.1.11.Yuhan Corporation
8.2. Key Findings
8.3. Recommendations
